Bristol-Myers gets FDA okay for injectable Opdivo

[ad_1] Arbutus Biopharma (NASDAQ:ABUS) announced on Monday its 2025 corporate objectives and provided a financial update. The company had cash, cash equivalents and investments in marketable securities totaling approximately $123 million as of December 31, 2024. The company expects to significantly [ad_2]

[ad_1] TBE/iStock Editorial via Getty Images Novartis (NYSE:NVS) said the U.S. Court of Appeals for the Federal Circuit has upheld the company’s U.S. combination patent for its blockbuster cardiac drug Entresto, also known as sacubitril/valsartan. The Swiss drugmaker said it will work to enforce the patent [ad_2]

[ad_1] Huntington Bancshares Non-GAAP EPS of $0.34 beats by $0.02, revenue of $1.95B beats by $60M [ad_2]